Stay updated with breaking news from Phase 3 Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The company had in August received the Drug Controller General of India's nod for conducting phase 2 clinical trials of the nasal vaccine
A peer review of the jab is expected in two to four months after it was given to scientific journals, Raches Ella Project Lead COVID-19 Vaccines at Bharat Biotech said on Wednesday
Positive Data from Completed InRhythm Phase 2 Study Demonstrate Safe and Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Plans to Initiate RESTORE1: Single Pivotal Phase 3 Trial in Atrial Fibrillation in Q3 2021; Data Expected 2H 2022 Appointment of Angela Wang as CFO Strengthens Management Team and Supports Key Near-Term Financial and Operational Objectives SAN FRANCISCO, June 09, 2021 (GLOBE NEWSWIRE) -- InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutic
Beijing [China], May 27 (ANI): The Chinese drug maker Sinopharm has finally published the interim results of a phase 3 trial of its COVID-19 vaccine, however, the results do not cover some of the most vulnerable groups.
Bi Jingquan urges Chinese pharmaceutical firms to be more transparent to build public trust in their products.